Brokerages Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) Target Price at $20.88

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been given an average rating of “Moderate Buy” by the eight brokerages that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $20.88.

A number of research firms have commented on TEVA. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Barclays raised their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Finally, StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.55% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several large investors have recently modified their holdings of TEVA. UMB Bank n.a. lifted its holdings in shares of Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares in the last quarter. Smithfield Trust Co increased its position in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after acquiring an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries during the third quarter worth about $50,000. Claro Advisors LLC bought a new position in Teva Pharmaceutical Industries in the third quarter valued at approximately $52,000. Finally, Venturi Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $60,000. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Up 0.5 %

Shares of NYSE TEVA opened at $22.21 on Thursday. Teva Pharmaceutical Industries has a 52-week low of $10.34 and a 52-week high of $22.25. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The business has a fifty day moving average of $17.89 and a two-hundred day moving average of $17.56. The stock has a market cap of $25.16 billion, a PE ratio of -26.13, a PEG ratio of 0.99 and a beta of 0.79.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.